Sun Pharma signs Definitive Agreement to Acquire Organon Sun Pharmaceutical Industries Limited and Organon & Co. have finalized a deal under which Sun Pharma will acquire all outstanding shares of Organon for US$14.00 per share in an all-cash transaction. The enterprise value of the deal is set at US$11.75 billion, marking a significant expansion for both companies. The acquisition, expected to close in early 2027, is subject to regulatory approvals and Organon stockholder approval. Organon, a global healthcare company spun off from Merck in 2021, specializes in women’s health and general medicines, with a portfolio of over 70 products. Its operations span 140 countries, including major markets such as the U.S., Europe, China, Canada, and Brazil. The company maintains six manufacturing facilities across the European Union and emerging markets, supporting its global footprint. Organon’s revenue for the year ended December 31, 2025, totaled US$6.2 billion, with Adjusted EBITDA of US$1.9 billion. It also reported debt of US$8.6 billion and a cash balance of US$574 million, bolstered by a recent divestiture that generated US$440 million in upfront payments. The acquisition aligns with Sun Pharma’s strategy to strengthen its Innovative Medicines business and expand its presence in biosimilars. The combined entity will become a top-25 global pharmaceutical company with projected revenue of US$12.4 billion, positioning it as a leader in Established Brands/Branded Generics and a top-3 player in women’s health. Sun Pharma’s entry into biosimilars as a Top-10 global player is a key outcome, leveraging Organon’s expertise and market reach. The deal also aims to enhance long-term value creation through synergies, including revenue upside opportunities and improved cash flow.#sun_pharma #merck #organon_co #organon #sun_pharmaceutical_industries_limited
Sun Pharma Acquires U.S. Firm Organon in $11.75 Billion Deal Sun Pharmaceutical Industries, India’s largest drugmaker, announced a major acquisition of New Jersey-based Organon & Co in an all-cash deal valued at $11.75 billion, including debt. The transaction involves purchasing all outstanding shares of Organon for $14.00 per share, significantly boosting Sun Pharma’s revenue to $12.4 billion. This places the company among the top 25 global pharmaceutical firms, according to the joint statement from both entities. Organon, which was spun off from Merck in 2021, specializes in women’s health and biosimilars. The U.S.-based company operates in over 140 countries and has more than 70 products in its portfolio. The acquisition is part of Sun Pharma’s strategy to expand its innovative medicines business, which currently covers dermatology, ophthalmology, and onco-dermatology. With the deal, the Indian company aims to increase its innovative medicines segment’s contribution to total sales from 20% to 27% by the financial year ending March 2025. The deal’s financial implications are notable. Organon carries a net debt-to-EBITDA ratio of 4 times, while Sun Pharma is described as “net positive.” Post-acquisition, the combined entity’s net debt-to-EBITDA ratio will drop to 2.3 times. Organon’s debt stood at $8.6 billion as of December 2025, with a cash balance of $574 million. Sun Pharma’s executive chairman, Dilip Shanghvi, highlighted the strategic value of the acquisition, stating that Organon’s portfolio and global reach complement Sun Pharma’s existing operations. The U.S. market, a key focus for Sun Pharma, will benefit from Organon’s presence, which includes sales in the U.S., Europe, China, Canada, and Brazil. Organon’s six manufacturing facilities span the European Union and emerging markets.#merck #sun_pharmaceutical_industries #organon_co #dilip_shanghvi #taro_pharma
S&P 500 Stock to Target This Week and 2 We Ignore The S&P 500 index includes the largest and most well-known companies, making it a popular choice for investors seeking stability. However, not all large-cap stocks perform equally, as some face challenges like slowing growth, declining margins, or increased competition. Selecting the right stocks requires more than just picking big names, and this analysis highlights one strong contender and two to avoid. Two Stocks to Avoid: CVS Health (CVS) has struggled with growth, as its 6% annual revenue increases over the past two years lagged behind peers. Sales are expected to remain flat for the next 12 months, and profitability has declined, with earnings per share dropping 2.1% annually despite revenue growth. The company’s stock trades at 10x forward P/E, reflecting investor caution. PulteGroup (PHM) also faces challenges, with revenue growth of 3.8% over the last two years falling short of industry averages. Earnings per share have declined 1.4% annually, raising concerns about long-term value. The stock’s 11.2x forward P/E ratio suggests a cautious outlook, with diminishing returns on capital indicating potential issues with profitability. One Stock to Consider: Merck (MRK), with a $286 billion market cap, stands out due to its dominant position in the pharmaceutical industry. Its $65.09 billion in revenue creates significant barriers to entry, while adjusted operating margins improved by 30.8 percentage points over two years. The company generates strong free cash flow, offering flexibility for growth investments or shareholder returns. Merck’s stock trades at 22.1x forward P/E, reflecting its strong fundamentals and market position. Additional recommendations include stocks with strong fundamentals and recent momentum, though specific names are not detailed here.#s_p_500 #merck #cvs_health #pultegroup #phm
Merck Nears $6 Billion Acquisition of Terns Pharma to Expand Cancer Portfolio Pharmaceutical company Merck is nearing a roughly $6 billion all-cash deal to acquire biotech firm Terns Pharma, according to reports. The potential acquisition is part of Merck’s strategy to strengthen its oncology division, which focuses on cancer treatments. The company is actively building a dedicated cancer division centered around its blockbuster drug Keytruda, which is expected to face patent expiration in 2028. This move aims to secure its position in the market as competition in oncology therapies intensifies. The deal, which is said to be in advanced stages of negotiations, could see a final agreement within the next few days. Terns Pharma, which specializes in developing treatments for chronic myeloid leukemia, has seen its shares rise by approximately 10% in after-hours trading following the news. However, Merck and Terns Pharma have not yet commented on the potential acquisition, leaving details about the terms and timeline of the deal undisclosed. Merck’s focus on oncology reflects broader industry trends as pharmaceutical companies seek to diversify their portfolios and address unmet medical needs. Keytruda, a PD-1 inhibitor, has been a major revenue driver for Merck, but its patent expiration in 2028 could threaten its long-term profitability. By acquiring Terns Pharma, Merck may gain access to innovative therapies and expand its pipeline of cancer treatments, potentially offsetting the loss of Keytruda’s exclusivity. The acquisition also highlights the growing importance of partnerships and mergers in the pharmaceutical sector. As drug development costs rise and regulatory hurdles increase, companies are increasingly turning to acquisitions to accelerate innovation and reduce financial risks.#merck #keytruda #terns_pharma #chronic_myeloid_leukemia #pd_1_inhibitor
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline Merck announced on Wednesday that it will acquire U.S. biotech firm Terns Pharmaceuticals for $6.7 billion, marking the third major acquisition the company has made in the past year. The deal involves Merck purchasing Terns at $53 per share in cash, valuing the company at approximately $6.7 billion. This represents a 6% premium over Terns’ closing stock price on Tuesday, according to CNBC’s calculations. The transaction is expected to close in the second quarter of the year. The acquisition is part of Merck’s strategy to strengthen its portfolio as its top-selling cancer drug, Keytruda, faces the loss of patent protection in 2028. Terns is developing a potential treatment for a specific type of leukemia, which analysts believe could become a multibillion-dollar drug. The therapy is positioned to compete with Novartis’ Scemblix, a currently successful treatment for the same condition. Terns’ stock has experienced significant growth in recent months, driven by investor optimism surrounding its experimental drug. The medication showed promising results in an early trial conducted late last year, fueling market speculation. On Wednesday, Terns shares surged as much as 15% in early trading after media reports indicated the companies were nearing a deal. The stock had already risen over 5.3% in premarket trading, reflecting heightened investor interest. Terns’ stock has also seen a substantial increase over the past year, underscoring the market’s confidence in its pipeline. The acquisition underscores Merck’s commitment to expanding its oncology offerings amid the impending patent expiration of Keytruda, which has been a cornerstone of its revenue for years.#novartis #merck #terns_pharmaceuticals #keytruda #scemblix
